首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL34 |
| Uniprot No | Q6ZMJ4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-242aa |
| 氨基酸序列 | NEPLEMWPLT QNEECTVTGF LRDKLQYRSR LQYMKHYFPI NYKISVPYEG VFRIANVTRL QRAQVSEREL RYLWVLVSLS ATESVQDVLL EGHPSWKYLQ EVETLLLNVQ QGLTDVEVSP KVESVLSLLN APGPNLKLVR PKALLDNCFR VMELLYCSCC KQSSVLNWQD CEVPSPQSCS PEPSLQYAAT QLYPPPPWSP SSPPHSTGSV RPVRAQGEGL LP |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-34重组蛋白的3篇代表性文献摘要(内容为模拟概括，仅供参考)：
---
1. **文献名称**: *IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia*
**作者**: Greter M, et al.
**摘要**: 该研究通过重组IL-34蛋白实验，证实IL-34与CSF1R受体的特异性结合，并揭示其在朗格汉斯细胞和小胶质细胞发育中的关键作用，为神经免疫调控提供机制依据。
---
2. **文献名称**: *Recombinant human IL-34 promotes monocyte survival and triggers M2-like macrophage polarization*
**作者**: Baghdadi M, et al.
**摘要**: 研究利用重组人源IL-34蛋白处理单核细胞，发现其能通过激活ERK信号通路抑制细胞凋亡，并诱导M2型巨噬细胞极化，提示其在炎症和肿瘤微环境中的潜在调控功能。
---
3. **文献名称**: *IL-34 accelerates tumor metastasis through CSF1R-dependent NF-κB pathway*
**作者**: Liu H, et al.
**摘要**: 通过体外重组IL-34蛋白刺激实验，证明其通过结合CSF1R激活NF-κB通路，增强肿瘤细胞侵袭能力，为靶向IL-34的癌症治疗策略提供理论基础。
---
注：以上文献信息为示例，实际研究需通过学术数据库(如PubMed)检索具体文献。
Interleukin-34 (IL-34) is a cytokine first identified in 2008 as a second ligand for the colony-stimulating factor 1 receptor (CSF-1R), a key regulator of monocyte/macrophage lineage development and function. Structurally distinct from the classical ligand CSF-1. IL-34 binds to overlapping but non-identical regions of CSF-1R, activating similar downstream signaling pathways such as PI3K/AKT and MAPK. This functional redundancy is balanced by unique expression patterns: IL-34 shows tissue-specific distribution in the central nervous system, liver, skin, and inflamed tissues, suggesting specialized roles in neurodevelopment, immune regulation, and disease pathogenesis.
Recombinant IL-34 proteins are engineered using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and bioactivity. These proteins typically include tags (e.g., His-tag) for purification and detection. Production involves codon optimization, transfection, and multi-step chromatography purification, followed by rigorous quality control using SDS-PAGE, Western blot, and functional assays like cell proliferation tests on CSF-1R-expressing cells.
Research applications span immunology, oncology, and neurology. IL-34 modulates macrophage differentiation, osteoclastogenesis, and microglial homeostasis, linking it to diseases such as rheumatoid arthritis, cancer metastasis, and Alzheimer’s. In cancer, IL-34 exhibits dual roles: promoting tumor-associated macrophage infiltration (pro-tumorigenic) or enhancing anti-tumor immunity depending on context. Its neural functions involve synaptic pruning and neuroprotection, highlighting therapeutic potential in neurodegenerative disorders.
Therapeutic targeting of IL-34-CSF-1R axis is under investigation, with recombinant IL-34 serving as a tool to dissect signaling mechanisms or as a potential biologic. Challenges include optimizing pharmacokinetics and understanding isoform-specific effects, as alternative splicing generates variants with altered bioactivity. Ongoing studies aim to clarify its role in immune tolerance, tissue repair, and cross-talk with other cytokine networks.
×
